Gerald went from not thinking one was needed to the company can do one at any time without shareholder's approval. While I am fine with that, he hasn't been consistent or exactly candid on the subject. He could have from the get go given both responses and left it at that. I can only speculate that Gerald thought certain news items released this year would be enough to move the pps up to a point where a RS wouldn't be necessary to uplist. If that was his thinking, he obviously was severely wrong as most of us have been. No one would have believed you if you had said 6 months ago the pps would be stuck in the 7 or 8 cent range in Dec. But here we are still waiting for the launch of Lympro. We might just be getting a lump of coal for Xmas.